Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proliferative Diabetic Retinopathy Clear all
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00130845
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

NCT00445003
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
Drug · Behavioral · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
56
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Jul 22, 2026, 8:29 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 22, 2026, 8:29 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

NCT04702048
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Aflibercept Injection, Sham injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 22, 2026, 8:29 AM EDT
Completed No phase listed Observational

Diabetes PRP and OCT

NCT01928550
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

NCT03197870
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
AKB-9778, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 22, 2026, 8:29 AM EDT
Withdrawn Phase 3 Interventional

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

NCT01589718
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen, Sham
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

NCT00606138
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 22, 2026, 8:29 AM EDT
Not listed Phase 2 Interventional

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
OPL-0401 Dose 1, Placebo
Drug
Lead sponsor
Valo Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Mountain View, California • Riverside, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jul 22, 2026, 8:29 AM EDT
Withdrawn Not applicable Interventional

UNITY VCS Vitreoretinal Surgery

NCT07054281
View directory record Official record
Conditions
Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction, Vitreous Hemorrhage, Proliferative Diabetic Retinopathy, Rhegmatogenous Retinal Detachment, Retained Lens Material in the Posterior Segment
Interventions
UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Laguna Hills, California • West Des Moines, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 22, 2026, 8:29 AM EDT
Terminated Phase 2 Interventional Results available

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

NCT00668785
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT04278417
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Propranolol for Diabetic Retinopathy

NCT01535495
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Propranolol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Results available

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341
View directory record Official record
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 22, 2026, 8:29 AM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jul 22, 2026, 8:29 AM EDT
Terminated Phase 2Phase 3 Interventional

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

NCT00664183
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Vitreosolve
Drug
Lead sponsor
Vitreoretinal Technologies, Inc.
Industry
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Santa Ana, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2009 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Jul 22, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation

NCT02995629
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy - High Risk
Interventions
laser indirect ophthalmoscopy pan retinal photocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 22, 2026, 8:29 AM EDT